10-Q · May 15, 2026
Neuphoria Therapeutics Inc. reported a significant decline in revenue, dropping to $0 for Q3 2026, compared to $15 million in Q3 2025. The company also recorded a net loss of $0.5 million for the quarter versus a net…
Earnings analysis · 10-K
NEUP earnings analysis
Filed September 18, 2026 · Our reading of the company's report
The latest report
Neuphoria’s fiscal 2026 results show a sharp deterioration in underlying operating performance: revenue fell 92.5% to $1.17 million, net loss expanded to $13.5 million, and operating cash use reached $12.4 million. The…
Read full summary
Neuphoria’s fiscal 2026 results show a sharp deterioration in underlying operating performance: revenue fell 92.5% to $1.17 million, net loss expanded to $13.5 million, and operating cash use reached $12.4 million. The company has substantially curtailed operations, discontinued its social anxiety program, paused PTSD development, and is relying on the proposed Scancell merger and contingent licensing economics for strategic value. Cash of $19.9 million provides a stated runway beyond the second quarter of fiscal 2028 under the reduced-cost plan, but the Merck clinical setback, material weakness, ongoing losses and potential dilution make the outlook high risk.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-3.06
- Operating margin
- -1400.4%
- Segment
- Single operating and reporting segment: discovery and development of allosteric ion channel modulators; revenue of $1.17 million in fiscal 2026.
What stood out
-
Strategic merger provides potential liquidity path
Management is pursuing a strategic transaction with Scancell announced July 23, 2026. Under the proposed transaction, existing Neuphoria stockholders are expected to own approximately 11.1% of the combined company, and the transaction includes contingent value rights tied to potential Merck, CTx CRC and other proceeds.
-
Cash runway extends beyond fiscal 2028
Cash and cash equivalents increased to $19.9 million at June 30, 2026 from $14.2 million a year earlier. Management believes current cash will fund operations beyond the second quarter of fiscal 2028, reflecting recent cost curtailments.
-
Substantial equity financing completed
The company raised $17.9 million net through financing activities, including approximately $18.5 million of gross proceeds from issuing 3,398,869 shares under its ATM facility, compared with $2.1 million gross ATM proceeds in fiscal 2025.
-
CTx CRC distribution generated revenue
Fiscal 2026 revenue was $1.17 million, including approximately $1.2 million from the CTx CRC collaboration. This demonstrates some recurring commercialization participation, although the company has not generated product revenue.
-
Large contingent Merck economics remain
The company remains eligible for up to $450 million in Merck milestone payments—$275 million of development milestones and $175 million of potential commercial milestones—plus royalties ranging from a low-single-digit percentage to a low-sub-teens percentage of qualifying net sales.
-
Restructuring sharply reduced cash burn
Cost reductions materially lowered direct R&D expense to $3.5 million from $9.0 million, a 60.6% decrease, after the company paused BNC210 PTSD development and discontinued the social anxiety disorder program.
What to watch
-
Lead clinical programs halted after trial failure
The AFFIRM-1 Phase 3 trial of BNC210 for social anxiety disorder did not meet its primary endpoint in October 2025; the company discontinued the SAD program and paused PTSD development while evaluating strategic transactions. The resulting fiscal 2026 restructuring included $1.4 million of employee termination costs and termination of substantially all employees.
-
Merck program failure removes key value driver
Merck canceled the Phase 2 MK-1167 Alzheimer’s trial on July 1, 2026 after an interim analysis found the drug did not meet efficacy criteria. Neuphoria recorded a $5.4 million goodwill impairment, and no Merck milestone payments were received in fiscal 2026, versus a $15.0 million milestone in fiscal 2025.
-
Material weakness in impairment controls
The company reported a material weakness in internal control over financial reporting because controls did not timely identify the goodwill impairment trigger. Disclosure controls were therefore deemed not effective as of June 30, 2026.
-
Losses and financing dependence remain acute
Net loss widened to $13.5 million from $0.4 million, while operating cash flow declined to negative $12.4 million from positive $0.1 million. The company has an accumulated deficit of $191.8 million and states that additional financing may be required if development activities resume.
-
Equity funding creates substantial dilution
Fiscal 2026 financing relied heavily on equity issuance: shares outstanding rose to 5,411,334 from 1,978,460, while the company issued 3,398,869 ATM shares. Further dilution is possible because the ATM facility was increased to $20.0 million and 1,054,381 warrant shares remained outstanding at a weighted-average exercise price of $11.88.
-
Merger completion remains conditional
The proposed Scancell merger is subject to stockholder approvals, Nasdaq listing approval, a concurrent financing of at least $75.0 million, and closing net cash of at least $10.0 million as of December 31, 2026 or closing. Either party may generally terminate if the merger is not completed by February 28, 2027, subject to a possible 60-day extension.
Management's outlook
The 10-K provides no numeric revenue or EPS guidance. Management states existing cash is expected to fund operations beyond the second quarter of fiscal 2028 under its current, cost-curtailed operating plan; annual outlook is otherwise deferred to company communications.
Earlier filings 4
10-Q · February 17, 2026
Neuphoria Therapeutics Inc. reported significant financial challenges in its Q2 2026 10-Q, showcasing a revenue decline to $0 amidst continued funding from equity sales. The company faced an accumulated deficit of…
10-Q · November 14, 2025
Neuphoria Therapeutics Inc. reported a challenging quarter with a significant net loss of $9.9 million for the three months ending September 30, 2025, up from a loss of $0.8 million in the prior year. Revenue figures…
10-K · September 29, 2025
Neuphoria Therapeutics Inc. reported a net loss of $0.4 million for the fiscal year ending June 30, 2025, compared to a loss of $15.5 million in the previous year, reflecting improvements largely due to milestone…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.